Details for Patent: 11,419,769
Which drugs does patent 11,419,769 protect, and when does it expire?
Patent 11,419,769 protects KYNMOBI and is included in one NDA.
This patent has thirty-nine patent family members in twenty countries.
Summary for Patent: 11,419,769
| Title: | Sublingual films | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Nathan John Bryson, Anthony John Giovinazzo, Scott David Barnhart, Michael Clinton Koons | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Sumitomo Pharma America Inc | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US16/409,257 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Patent 11,419,769: Apomorphine Sublingual Film Claims, Scope, Expiration Risk and Patent LandscapeUS Patent 11,419,769 protects a narrowly defined sublingual apomorphine film rather than apomorphine generally. Independent claim 1 requires an acid-addition salt of apomorphine, two specified molecular-weight polymer populations, a bilayer structure, and pyridoxine as the pH-neutralizing agent. The dependent claims add permeation enhancers, glycerol monostearate, plasticizers, starch derivatives, antioxidants, particle-size limits, stability requirements, pH limits, and three apomorphine hydrochloride dose ranges. The patent is closely aligned with the formulation technology used for KYNMOBI, the FDA-approved apomorphine hydrochloride sublingual film for treating "OFF" episodes in Parkinson's disease. Patent infringement risk is highest for a product that reproduces the claimed bilayer architecture, pyridoxine-containing neutralizing layer, polymer ranges, and apomorphine hydrochloride dosage strengths. What does US Patent 11,419,769 protect?The patent protects a pharmaceutical composition in unit-dose sublingual film form with five core technical requirements:
The claim is cumulative. A product must satisfy every limitation of claim 1 to infringe that claim literally. A product containing apomorphine in a sublingual film but lacking pyridoxine in a second layer would not literally satisfy the express bilayer limitation. The claim also requires two polymer molecular-weight classes. The low- and high-molecular-weight polymers may be different cellulose derivatives, or potentially the same polymer chemistry supplied in distinct molecular-weight grades. The claim language does not require a particular ratio between the low- and high-molecular-weight polymers. How does the claim structure affect infringement risk?The independent composition claim is narrower than a claim directed broadly to apomorphine films. Its principal limitations create several potential design-around paths:
Doctrine-of-equivalents risk remains fact-specific. A formulation that substitutes another vitamin or buffering compound for pyridoxine could still generate litigation if the substitute performs substantially the same function in substantially the same way with substantially the same result. The express selection of pyridoxine, however, gives the patent owner an argument that the claim deliberately excludes other neutralizing agents. What do claims 2 through 19 add?The dependent claims create narrower fall-back positions around the commercial formulation.
Claims 17 through 19 are commercially important because they can track marketed dose strengths. The claims specify apomorphine hydrochloride amounts, not necessarily the amount of active apomorphine base. A product label using equivalent salt amounts must be assessed against the claim's measurement convention and manufacturing specifications. What does the bilayer requirement mean?The claim requires a first layer containing the acid-addition salt of apomorphine and a second layer containing pyridoxine. The claim does not state that pyridoxine must be absent from the first layer, nor does it expressly require a separate physical backing layer. The critical issue is whether the product has two identifiable film layers with the claimed allocation of ingredients. A laminated or co-cast bilayer may fall within the claim if the layers remain materially distinct. A single homogeneous film containing both apomorphine and pyridoxine presents a stronger non-infringement position against the literal bilayer limitation, although the manufacturing process and final microstructure would matter. The patent therefore reaches beyond the active ingredient. It protects the spatial organization of the formulation:
What is the significance of pyridoxine?Pyridoxine, or vitamin B6, is the expressly claimed pH-neutralizing agent. In an apomorphine hydrochloride film, pyridoxine can help moderate acidity and support tolerability or dissolution behavior. Claim 1 makes pyridoxine a mandatory limitation, not an optional excipient. This creates an important distinction between:
The latter two categories may avoid literal infringement of claim 1 but could remain exposed to other patents in the same family or to claims with broader pH-modifier language. How do the particle-size and pH claims affect product scope?Claim 15 covers apomorphine particles with an effective particle size from 20 nm to 10 µm. The term "effective particle size" can require technical interpretation. It may refer to a measured particle-size distribution rather than a single particle diameter. Analytical method, dispersion medium, agglomeration, and sampling conditions can affect the result. Claim 16 requires a solution pH between 4.5 and 8.5 when the film is placed in 1 mL of unbuffered water at pH 7. That limitation is test-dependent. A party evaluating infringement would need to control:
Claims 12, 15 and 16 can therefore create evidentiary disputes even when the formulation appears compositionally similar. What method-of-use protection does US 11,419,769 provide?Claim 20 covers a method of treating Parkinson's disease by sublingually administering the composition of claim 1. Claim 21 narrows the treatment to alleviating an "OFF" episode. The method claims require use of the claimed composition. They do not cover every sublingual apomorphine product used in Parkinson's disease. A competing product would need to satisfy claim 1 before the treatment-use limitations become relevant. The method claims may have regulatory significance in an abbreviated new drug application if the branded label includes treatment of Parkinson's disease "OFF" episodes. A generic applicant could pursue a Paragraph IV certification against listed method-of-use patents or use a section viii statement for a patented indication, depending on the Orange Book listing and label carve-out feasibility. FDA-approved apomorphine products and their labeling must be reviewed separately from the patent claims. FDA identifies KYNMOBI as apomorphine hydrochloride sublingual film for intermittent treatment of "OFF" episodes in patients with Parkinson's disease. (U.S. Food and Drug Administration, 2023) What is the likely patent expiration date?US Patent 11,419,769 was issued on August 23, 2022. The expiration date cannot be determined from the claims alone because the controlling term depends on the earliest effective nonprovisional or international filing date, continuation-chain treatment, patent-term adjustment, terminal disclaimers, and any patent-term extension. The relevant term analysis is:
A reliable expiration date requires the USPTO patent-term data and the complete family prosecution history. The patent number and claim text alone do not establish the final enforceable expiration date. What is the Orange Book status of US 11,419,769?The patent number alone does not establish an Orange Book listing. Orange Book inclusion depends on whether the NDA holder submitted the patent to FDA, whether FDA accepted the listing, and whether the patent is listed against the relevant drug product and use. For a KYNMOBI-related analysis, the relevant review should compare:
FDA's Orange Book provides the regulatory listing framework, while the patent itself controls claim scope. A patent can be relevant to a product without being listed in the Orange Book, and an Orange Book listing does not establish ultimate validity or infringement. (FDA, 2024) How strong is the patent estate around this formulation?US 11,419,769 has meaningful product-specific value but a limited literal scope. Strengths
Weaknesses
Which companies are challenging the patent?The supplied information identifies no Paragraph IV certification, ANDA applicant, district-court action, inter partes review, post-grant review, or settlement agreement involving US 11,419,769. A complete challenger analysis requires matching the patent against:
The patent number alone does not establish that a generic company has challenged the patent. No conclusion about a live challenge or settlement should be drawn solely from the claims. Are biosimilar risks relevant?No. KYNMOBI is a chemically synthesized small-molecule drug containing apomorphine hydrochloride, not a biologic. Biosimilar approval under the Public Health Service Act is therefore not the relevant pathway. The competitive threat is an ANDA-based generic or an alternative 505(b)(2) product. The main barriers are formulation equivalence, sublingual performance, dose uniformity, film manufacturing, stability, drug-product patent claims and any Orange Book-listed method-of-use patents. What manufacturing and intellectual-property barriers exist?The most important manufacturing barriers are:
These barriers may support commercial differentiation even where a competitor avoids literal claim coverage. Manufacturing know-how, batch records, analytical methods, supplier specifications and trade secrets can provide protection beyond the patent claims. How does this patent compare with a broad apomorphine patent?
The patent is best viewed as a formulation and product patent. It is not a basic apomorphine composition patent and does not, by itself, block every route of administering apomorphine. Key Takeaways
FAQsDoes US 11,419,769 cover apomorphine tablets?No. The asserted claims require a sublingual film. A tablet would not literally satisfy the dosage-form limitation. Can a generic use a different pH-neutralizing agent?Potentially. A product using a neutralizer other than pyridoxine may avoid literal infringement of claim 1, but the full patent family and any other listed patents would need separate review. Does the patent cover apomorphine base?The claims provided require an acid-addition salt of apomorphine. Apomorphine base is not within that express limitation. Is a 30 mg apomorphine hydrochloride film automatically infringing?No. The product must also satisfy the other limitations, including the bilayer structure, pyridoxine-containing second layer and polymer requirements. Can a company avoid the patent by changing only the packaging?Usually not if the finished dosage form still satisfies the composition claims. Packaging changes may be relevant to claim 12's stability limitation, but they do not necessarily avoid claim 1. References
More… ↓ |
Drugs Protected by US Patent 11,419,769
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-001 | May 21, 2020 | DISCN | Yes | No | 11,419,769 | ⤷ Start Trial | Y | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Start Trial | |||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-002 | May 21, 2020 | DISCN | Yes | No | 11,419,769 | ⤷ Start Trial | Y | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Start Trial | |||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-003 | May 21, 2020 | DISCN | Yes | No | 11,419,769 | ⤷ Start Trial | Y | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Start Trial | |||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-004 | May 21, 2020 | DISCN | Yes | No | 11,419,769 | ⤷ Start Trial | Y | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,419,769
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2011343429 | ⤷ Start Trial | |||
| Australia | 2017200331 | ⤷ Start Trial | |||
| Australia | 2019200138 | ⤷ Start Trial | |||
| Brazil | 112013015204 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
